Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marco Mariani
Observed names:
M. Mariani,
Mariani, Marco
Institutions:
Vita-Salute San Raffaele University,
Yale Cancer Center,
Yale University,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
Observed institutions:
Vita-Salute San Raffaele University,
Yale Cancer Center,
Yale University,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma,
Sapienza University of Rome
show all 6
ORCID:
0009-0000-7444-8578
Observed ORCID:
0009-0000-7444-8578
OpenAlex ID:
A5113166698
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer
2025
·
Luca Licata
, Marco Mariani
, et al.
·
Clinical Cancer Research
·
13
PDF
Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy
2026
·
Giulia Notini
, Barbara Galbardi
, et al.
·
npj Precision Oncology
·
4
PDF
De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice
2026
·
Irene Persano
, Luca Licata
, et al.
·
Cancer Treatment Reviews
·
4
PDF
Bronchiolitis: A 9 years epidemic seasons analysis
2014
·
Marianna Ferrara
, Giulia Cangiano
, et al.
·
European Respiratory Journal
·
4
FastBindRank software: distillation-based framework for scalable virtual screening across ultra-large chemical libraries
2026
·
Dai, Jiawei
, Wang, Yueyue
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
1
FastBindRank dataset: Boltz-2 predictions of binding probability and log10(IC50) for 1.85 million random PubChem compounds targeting HDAC11
2026
·
Dai, Jiawei
, Wang, Yueyue
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
1
Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.
2026
·
Antonio Cigliola
, Brigida Anna Maiorano
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Low Rates of Discontinuation Unrelated to Disease Progression with Trastuzumab Deruxtecan in Metastatic Breast Cancer: A Real-World Study
2026
·
Luca Licata
, Francesca Patanè
, et al.
·
Cancers
Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive/HER2-negative breast cancer
2026
·
L. Licata
, M. Mariani
, et al.
·
Annals of Oncology
PDF
Time-dependent prognostic impact of tumor grade in stage I-III breast cancers
2026
·
M. Mariani
, M. Ochocki
, et al.
·
ESMO Open
Abstract A024: FastBindRank, a novel, scalable method for high-fidelity virtual screening of ultra-large chemical libraries idendtifies novel HDAC11 inhibitors
2026
·
Jiawei Dai
, Yueyue Wang
, et al.
·
Clinical Cancer Research
Distillation enables scalable high-fidelity virtual screening across ultra-large chemical libraries
2026
·
Jiawei Dai
, Yueyue Wang
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
Supplementary Figure S1 from Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer
2025
·
Luca Licata
, Marco Mariani
, et al.
Data from Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer
2025
·
Luca Licata
, Marco Mariani
, et al.
Show more works
View as search
Works count:
15
Citation count:
28
H-index:
4
I10-index:
1
Year
Topic
Type